Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$481.71 USD
+5.56 (1.17%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $481.72 +0.01 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
VRTX 481.71 +5.56(1.17%)
Will VRTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRTX
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
Zacks Market Edge Highlights: Vertex, Zillow RH, Super Micro Computer, Yum China
Insider Trades: How to Find the Top Stocks
Other News for VRTX
Capricor reports positive long-term data for DMD drug deramiocel
Vertex Pharmaceuticals (VRTX) Receives a Hold from Morgan Stanley
Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Vertex Pharmaceuticals resumed with a Market Perform at Raymond James
Vertex Pharmaceuticals reinstated with a Market Perform at Raymond James